Literature DB >> 430314

Constriction of the fetal ductus arteriosus after administration of indomethacin to the pregnant ewe.

D L Levin, L J Mills, M Parkey, J Garriott, W Campbell.   

Abstract

The prostaglandin synthetase inhibitor indomethacin was given orally or intravenously to pregnant ewes. This resulted in the fetal pulmonary to systemic arterial mean blood pressure difference across the ductus arteriosus rising significantly, presumably secondary to constriction of the ductus arteriosus. The pressure difference was due to pulmonary arterial hypertension, and not due to a fall in systemic arterial mean blood pressure. Fetal arterial blood gas tensions and pH values were normal throughout. In five experiments the pressure difference could be promptly but temporarily reversed by the administration of PGE1 into the fetal inferior vena cava. Indomethacin was present in fetal blood, and maternal plasma prostaglandin levels were suppressed. Indomethacin administration during pregnancy causes constriction of the fetal ductus arteriosus and fetal pulmonary arterial hypertension which, if severe, may cause rapid fetal death. It is possible that this mechanism may be one cause of persistent pulmonary hypertension or tricuspid insufficiency or both in the newborn infant.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 430314     DOI: 10.1016/s0022-3476(79)80043-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  13 in total

Review 1.  Patent ductus arteriousus in the premature neonate: current concepts in pharmacological management.

Authors:  C Hammerman; M Kaplan
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

Review 2.  Neonatal pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Crit Care Med       Date:  2010-03       Impact factor: 3.624

Review 3.  Patent ductus arteriosus: experimental aspects.

Authors:  J C Mott
Journal:  Arch Dis Child       Date:  1980-02       Impact factor: 3.791

Review 4.  The pharmacological treatment of patent ductus arteriosus. A review of the evidence.

Authors:  R J Barst; W M Gersony
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 5.  The central control of fetal breathing and skeletal muscle movements.

Authors:  G S Dawes
Journal:  J Physiol       Date:  1984-01       Impact factor: 5.182

6.  Persistent pulmonary hypertension and abnormal prostaglandin E levels in preterm infants after maternal treatment with naproxen.

Authors:  A R Wilkinson; A Aynsley-Green; M D Mitchell
Journal:  Arch Dis Child       Date:  1979-12       Impact factor: 3.791

Review 7.  Non-narcotic analgesics. Use in pregnancy and fetal and perinatal effects.

Authors:  M A Heymann
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Pulmonary vasculature changes associated with idiopathic closure of the ductus arteriosus and hydrops fetalis.

Authors:  G J Downing; D W Thibeault
Journal:  Pediatr Cardiol       Date:  1994 Mar-Apr       Impact factor: 1.655

Review 9.  Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn.

Authors:  Linda J Van Marter; Sonia Hernandez-Diaz; Martha M Werler; Carol Louik; Allen A Mitchell
Journal:  Pediatrics       Date:  2012-12-03       Impact factor: 7.124

Review 10.  Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors.

Authors:  A E Farah; F Rosenberg
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.